iDrip Stem Cells: This Is So Illegal…

By /

idrip therapy

If you could design a stem cell product sales campaign to be maximally illegal, then IMHO a company called iDrip has got you covered. These guys are selling culture-expanded umbilical cord “stem cells” directly to providers. Let dig in.

What Is iDrip Therapy?

iDrip Therapy is a company out of Pheonix, Arizona that was begun by a personal trainer and press release writer Brandon Collins. iDrip usually offers IV vitamin packages direct to consumers and uses an RN or paramedic to go out to patient homes to hook up their cocktails. They have two medical directors, both ER physicians.

Join us for a free Regenexx webinar.

The Email that Altered Me

“Subject: Stem Cells and Exosomes – Direct Supply

Hi Dr. X, my name is Mimi and I work with iDrip Therapy to supply stem cells and exosomes to hospitals and clinics like yours. I’m reaching out, because I can offer you high quality stem cells at discounted prices.

 The stem cells we offer are Cultivated Umbilical Cord Mesenchymal Stem Cells. As an extension of fetal cells, UCMSC’s offer high plasticity and decreased risk of rejection or GVHD.

We are working with a “Class 100” lab located in California that specializes in advanced therapies, such as regenerative medicine. The lab has a registered IND account and FDA approval to store, work with, and distribute these cells and exosomes. Our cultivated stem cells and exosomes offer higher efficacy and better quality compared to our competitors who use uncultivated cells.”

Why This Is CRAZY

First, let’s dissect what Mimi sent my colleague:

  • iDrip offers “cultivated” umbilical cord stem cells. From this email and looking at their website, they appear to be offering culture-expanded mesenchymal stem cells derived from umbilical cord blood.
  • To do this legally, the company selling the cells or iDrip would have to have an FDA-approved BLA (Biologics License Application) which takes about 5-7 years of clinical trials per medical indication to get. Meaning that in order to treat arthritis, that would be one drug approval and in order to treat something else yet another drug approval.
  • An “IND” is an FDA approval only to study a drug product (the cultivated cells) in a specific clinical study with strict inclusion and exclusion criteria. Meaning that there is no way that the FDA would allow iDrip or any other company to use these cells outside of a study to be given to random people in physician’s offices or at their homes. Hence the term “registered IND account” makes no sense. Meaning that contrary to what iDrip wrote in this email, the company has no FDA approval to “store, work with, and distribute these cells and exosomes”. How do I know that? At the time of this writing, there is no FDA approved culture-expanded umbilical cord derived drug product.
  • They also claim that these cells have a decreased risk for GVHD. That’s Graft vs. Host Disease. All umbilical cord transplants are matched between the donor and recipient, which is what reduces the chance of rejection (GVHD) (1-5). If these cells are isolated and culture-expanded, there could be a lower chance of rejection, but since this cell type has not been cleared yet with any FDA approval, nobody has any idea of how the body would respond to this product. To learn more about GVHD, see my video below:
Join us for a free Regenexx webinar.

Not Knowing Which End Is Up

IMHO, it’s one thing to sell culture-expanded stem cells without an FDA drug approval, but quite another to have no idea which end is up based on what you write on your website. Let’s take a look at this statement and use it to learn something about cultured stem cells:

This is the statement that makes no sense: “The blood is then sent for cell sorting of the RNA and DNA extractor making the stem cell transplant a universal donor.” What they are trying to reference here is FACS or Fluorescence-Activated Cell Sorting. This works by an antibody binding a specific protein on a cell’s surface and then the machine deciding which cells have been marked in that way in order to sort the cells. To learn more about this concept of cell surface markers on stem cells, see my video below:

The statement that sorting cells has something to do with RNA and DNA and adding the term “extractor” makes no scientific sense. This statement was clearly written by somebody without any basic knowledge of stem cells and how they are isolated for culture.

The upshot? Would I allow a family member to get culture-expanded umbilical cord stem cells placed in my veins? Heck no. This is not an FDA-approved product as the agency has approved no culture-expanded cell line for clinical use to be delivered IV for any of the indications listed on the iDrip website. I think the uneducated writer of this website has confused a number of concepts. For example a 361 tissue registration and an FDA 351 drug approval. One is a simple 45-minute online registration and the other is a 5-7 year approval process per disease that costs hundreds of millions of dollars. So for iDrip, IMHO what they’re selling is clearly being misrepresented.



(1) Eapen, Mary et al. Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, Volume 20, Issue 10, 1485 – 1492.

(2) Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923–1930.

(3) Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood Jul 2014, 124 (3) 363-373; DOI: 10.1182/blood-2014-01-514786

(4) Lee SJ. Classification systems for chronic graft-versus-host disease. Blood Jan 2017, 129 (1) 30-37; DOI: 10.1182/blood-2016-07-686642

(5) Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood Jul 2014, 124 (3) 374-384; DOI: 10.1182/blood-2014-01-514752

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Get Blog Updates by Email

We do not sell, or share your information to third party vendors.

By submitting the form you agree that you’ve read and consent to our Privacy Policy. We may use email, phone, or other electronic means to communicate information about Regenexx.

We will provide information to help you decide whether you want to schedule an evaluation with a Regenexx Physician.

Insurance typically covers evaluations and diagnostic testing (if recommended). Most insurance plans currently do not cover Regenexx Procedures.

Category: Uncategorized
Copyright © Regenexx 2021. All rights reserved.



9035 Wadsworth Pkwy #1000
Westminster, CO 80021


*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.